Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Roman Zilbershtein"'
Autor:
Charles Piwko, Roman Zilbershtein, R. Jensen, M Hemels, Hanna Pudas, Thomas R. Einarson, Christel N Bø, Colin Vicente
Publikováno v:
Nordic Journal of Psychiatry. 68:416-427
To determine the cost-effectiveness of long-acting injectable (LAI) antipsychotics for chronic schizophrenia in Sweden.A 1-year decision tree was developed for Sweden using published data and expert opinion. Five treatment strategies lasting 1 year w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccefc2444af765e18e6d4400552e2e55
https://doi.org/10.3109/08039488.2013.852243
https://doi.org/10.3109/08039488.2013.852243
Publikováno v:
Journal of Medical Economics. 16:1089-1095
The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots.An existing 1-year decision-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d891a9217c6a8d765d132f83c4cfe84
https://doi.org/10.3111/13696998.2013.820193
https://doi.org/10.3111/13696998.2013.820193
Autor:
Hanna Pudas, Thomas R. Einarson, Roman Zilbershtein, Colin Vicente, Michiel E. H. Hemels, Christel N. Bø, Charles Piwko
Publikováno v:
Acta Neuropsychiatrica. 25:85-94
ObjectivePaliperidone palmitate long‐acting injection (PP‐LAI) has recently been approved for treatment of chronic schizophrenia. Its cost‐effectiveness has not been established. The objective was to compare direct costs and outcomes between PP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2dabd966c917bdea57b2a9b3897952f
https://doi.org/10.1111/j.1601-5215.2012.00670.x
https://doi.org/10.1111/j.1601-5215.2012.00670.x
Autor:
Thomas R. Einarson, Colin Vicente, R. Jensen, Charles Piwko, Roman Zilbershtein, M Hemels, Hanna Pudas
Publikováno v:
Journal of medical economics. 16(9)
In Finland, regional rates of schizophrenia exceed those in most countries, impacting the healthcare burden. This study determined the cost-effectiveness of long-acting antipsychotic (LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e199115b8db8a8f625e011be3c70855
https://pubmed.ncbi.nlm.nih.gov/23844621
https://pubmed.ncbi.nlm.nih.gov/23844621
Autor:
Dionyssios Potamitis-Komis, Colin Vicente, Konstantina Paparouni, Thomas R. Einarson, Maria Geitona, Panagiotis Kakkavas, Periklis Paterakis, Dimitrios Ploumpidis, Alexandros Chaidemenos, Theodoros Mougiakos, Charles Piwko, Vasiliki Karpouza, R. Jensen, Roman Zilbershtein, M Hemels
Publikováno v:
Annals of General Psychiatry
Annals of General Psychiatry, Vol 11, Iss 1, p 18 (2012)
Annals of General Psychiatry, Vol 11, Iss 1, p 18 (2012)
Background Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d83fc9574033b8d6274e60e1b071d9
https://pubmed.ncbi.nlm.nih.gov/22747533
https://pubmed.ncbi.nlm.nih.gov/22747533
Autor:
R. Jensen, Miroslav Herceg, Thomas R. Einarson, Vlado Jukić, M Hemels, Roman Zilbershtein, Ante Silić, Tatjana Tomljanovic, Igor Filipčić, Miro Jakovljević
Publikováno v:
Value in Health Regional Issues. (2):181-188
Objectives: As a nation with a developing economy, Croatia is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. We conducted a pharmacoeconomic analysis to determine the cost-effectiveness of atypic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016e691fc86d21ffd336dedb562ccaec